Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to
evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPĪ± monoclonal antibody, as
monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).